{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T15:36:24Z","timestamp":1773675384423,"version":"3.50.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2012,1,11]],"date-time":"2012-01-11T00:00:00Z","timestamp":1326240000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1007\/s00277-011-1377-y","type":"journal-article","created":{"date-parts":[[2012,1,9]],"date-time":"2012-01-09T20:03:23Z","timestamp":1326139403000},"page":"847-856","source":"Crossref","is-referenced-by-count":26,"title":["The proteasome inhibitor bortezomib targets cell cycle and apoptosis and acts synergistically in a sequence-dependent way with chemotherapeutic agents in mantle cell lymphoma"],"prefix":"10.1007","volume":"91","author":[{"given":"Grit","family":"Hutter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malte","family":"Rieken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Pastore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Weigert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvonne","family":"Zimmermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Weinkauf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Hiddemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Dreyling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,1,11]]},"reference":[{"key":"1377_CR1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0092-8674(94)90396-4","volume":"79","author":"A Ciechanover","year":"1994","unstructured":"Ciechanover A (1994) The ubiquitin\u2013proteasome proteolytic pathway. Cell 79:13\u201321","journal-title":"Cell"},{"key":"1377_CR2","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1158\/1078-0432.CCR-07-2218","volume":"14","author":"RZ Orlowski","year":"2008","unstructured":"Orlowski RZ, Kuhn DJ (2008) Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res 14:1649\u20131657","journal-title":"Clin Cancer Res"},{"key":"1377_CR3","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S1535-6108(04)00120-5","volume":"5","author":"J Adams","year":"2004","unstructured":"Adams J (2004) The development of proteasome inhibitors as anticancer drugs. Cancer Cells 5:417\u2013421","journal-title":"Cancer Cells"},{"key":"1377_CR4","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s12094-006-0176-8","volume":"8","author":"C Montagut","year":"2006","unstructured":"Montagut C, Rovira A, Albanell J (2006) The proteasome: a novel target for anticancer therapy. Clin Transl Oncol 8:313\u2013317","journal-title":"Clin Transl Oncol"},{"key":"1377_CR5","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","volume":"348","author":"PG Richardson","year":"2003","unstructured":"Richardson PG, Barlogie B, Berenson J et al (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348:2609\u20132617","journal-title":"N Engl J Med"},{"key":"1377_CR6","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1097\/01.cco.0000245320.34658.bd","volume":"18","author":"PG Richardson","year":"2006","unstructured":"Richardson PG, Mitsiades C, Ghobrial I, Anderson K (2006) Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma. Curr Opin Oncol 18:598\u2013608","journal-title":"Curr Opin Oncol"},{"key":"1377_CR7","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.2146\/ajhp070272","volume":"65","author":"KN Utecht","year":"2008","unstructured":"Utecht KN, Kolesar J (2008) Bortezomib: a novel chemotherapeutic agent for hematologic malignancies. Am J Health Syst Pharm 65:1221\u20131231","journal-title":"Am J Health Syst Pharm"},{"key":"1377_CR8","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/j.1365-2141.2009.07775.x","volume":"146","author":"J Gerecitano","year":"2009","unstructured":"Gerecitano J, Portlock C, Moskowitz C et al (2009) Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma. Br J Haematol 146:652\u2013655","journal-title":"Br J Haematol"},{"key":"1377_CR9","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1365-2141.2008.07466.x","volume":"145","author":"OA O\u2019Connor","year":"2009","unstructured":"O\u2019Connor OA, Moskowitz C, Portlock C et al (2009) Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre Phase 2 clinical trial. Br J Haematol 145:34\u201339","journal-title":"Br J Haematol"},{"key":"1377_CR10","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/annonc\/mdn656","volume":"20","author":"A Goy","year":"2009","unstructured":"Goy A, Bernstein SH, Kahl BS et al (2009) Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol 20:520\u2013525","journal-title":"Ann Oncol"},{"key":"1377_CR11","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2217\/14796694.4.2.149","volume":"4","author":"KS Suh","year":"2008","unstructured":"Suh KS, Goy A (2008) Bortezomib in mantle cell lymphoma. Future Oncol 4:149\u2013168","journal-title":"Future Oncol"},{"key":"1377_CR12","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2005.04.6789","volume":"24","author":"SJ Strauss","year":"2006","unstructured":"Strauss SJ, Maharaj L, Hoare S et al (2006) Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. J Clin Oncol 24:2105\u20132112","journal-title":"J Clin Oncol"},{"key":"1377_CR13","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","volume":"24","author":"RI Fisher","year":"2006","unstructured":"Fisher RI, Bernstein SH, Kahl BS et al (2006) Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 24:4867\u20134874","journal-title":"J Clin Oncol"},{"key":"1377_CR14","first-page":"687","volume":"9","author":"I Jeremias","year":"1998","unstructured":"Jeremias I, Debatin KM (1998) TRAIL induces apoptosis and activation of NFkappaB. Eur Cytokine Netw 9:687\u2013688","journal-title":"Eur Cytokine Netw"},{"key":"1377_CR15","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1182\/blood-2002-06-1768","volume":"101","author":"N Mitsiades","year":"2003","unstructured":"Mitsiades N, Mitsiades CS, Richardson PG et al (2003) The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 101:2377\u20132380","journal-title":"Blood"},{"key":"1377_CR16","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/j.1600-0609.2004.00406.x","volume":"4","author":"M Duechler","year":"2005","unstructured":"Duechler M, Linke A, Cebula B et al (2005) In vitro cytotoxic effect of proteasome inhibitor bortezomib in combination with purine nucleoside analogues on chronic lymphocytic leukaemia cells. Eur J Haematol 4:407\u2013417","journal-title":"Eur J Haematol"},{"key":"1377_CR17","doi-asserted-by":"crossref","unstructured":"Orlowski RZ (2005) The ubiquitin proteasome pathway from bench to bedside. Hematol Am Soc Hematol Educ Program 220\u2013225","DOI":"10.1182\/asheducation-2005.1.220"},{"key":"1377_CR18","first-page":"2505","volume":"8","author":"C Aghajanian","year":"2002","unstructured":"Aghajanian C, Soignet S, Dizon DS et al (2002) A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 8:2505\u20132511","journal-title":"Clin Cancer Res"},{"key":"1377_CR19","doi-asserted-by":"crossref","first-page":"4420","DOI":"10.1200\/JCO.2002.01.133","volume":"20","author":"RZ Orlowski","year":"2002","unstructured":"Orlowski RZ, Stinchcombe TE, Mitchell BS et al (2002) Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 20:4420\u20134427","journal-title":"J Clin Oncol"},{"key":"1377_CR20","doi-asserted-by":"crossref","first-page":"4441","DOI":"10.1182\/blood-2006-07-034173","volume":"109","author":"P P\u00e9rez-Gal\u00e1n","year":"2007","unstructured":"P\u00e9rez-Gal\u00e1n P, Rou\u00e9 G, Villamor N, Campo E, Colomer D (2007) The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak. Blood 109:4441\u20134449","journal-title":"Blood"},{"key":"1377_CR21","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s00280-007-0543-3","volume":"61","author":"D Rolland","year":"2008","unstructured":"Rolland D, Camara-Clayette V, Barbarat A et al (2008) Farnesyltransferase inhibitor R115777 inhibits cell growth and induces apoptosis in mantle cell lymphoma. Cancer Chemother Pharmacol 61:855\u2013863","journal-title":"Cancer Chemother Pharmacol"},{"key":"1377_CR22","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/sj.leu.2404471","volume":"21","author":"T Haritunians","year":"2007","unstructured":"Haritunians T, Mori A, O\u2019Kelly J, Luong QT, Giles FJ, Koeffler HP (2007) Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma. Leukemia 21:333\u2013339","journal-title":"Leukemia"},{"key":"1377_CR23","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1600-0609.2007.00995.x","volume":"80","author":"U Heider","year":"2008","unstructured":"Heider U, von Metzler I, Kaiser M et al (2008) Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma. Eur J Haematol 80:133\u2013142","journal-title":"Eur J Haematol"},{"key":"1377_CR24","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1182\/blood-2007-12-130781","volume":"112","author":"L Paoluzzi","year":"2008","unstructured":"Paoluzzi L, Gonen M, Bhagat G et al (2008) The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies. Blood 112:2906\u20132916","journal-title":"Blood"},{"key":"1377_CR25","doi-asserted-by":"crossref","first-page":"5416","DOI":"10.1158\/1078-0432.CCR-08-0150","volume":"14","author":"RJ Jones","year":"2008","unstructured":"Jones RJ, Chen Q, Voorhees PM et al (2008) Inhibition of the p53 E3 ligase HDM-2 induces apoptosis and DNA damage\u2013independent p53 phosphorylation in mantle cell lymphoma. Clin Cancer Res 14:5416\u20135425","journal-title":"Clin Cancer Res"},{"key":"1377_CR26","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1158\/1078-0432.CCR-08-0399","volume":"15","author":"Y Tabe","year":"2009","unstructured":"Tabe Y, Sebasigari D, Jin L et al (2009) MDM2 antagonist nutlin-3 displays antiproliferative and proapoptotic activity in mantle cell lymphoma. Clin Cancer Res 15:933\u2013942","journal-title":"Clin Cancer Res"},{"key":"1377_CR27","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1200\/JCO.2005.11.030","volume":"23","author":"SV Rajkumar","year":"2005","unstructured":"Rajkumar SV, Richardson PG, Hideshima T, Anderson KC (2005) Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 23:630\u2013639","journal-title":"J Clin Oncol"},{"key":"1377_CR28","first-page":"61","volume-title":"Synergism and antagonism in chemotherapy","author":"TC Chou","year":"1991","unstructured":"Chou TC (1991) The median-effect principle and the combination index for quantitation of synergism and antagonism. In: Chou TC, Rideout DC (eds) Synergism and antagonism in chemotherapy. Academic, San Diego, pp 61\u2013102"},{"key":"1377_CR29","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","volume":"22","author":"TC Chou","year":"1984","unstructured":"Chou TC, Talalay P (1984) Quantitative analysis of doseeffect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27\u201355","journal-title":"Adv Enzyme Regul"},{"key":"1377_CR30","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.leukres.2005.11.013","volume":"30","author":"J Camps","year":"2006","unstructured":"Camps J, Salaverria I, Garcia MJ et al (2006) Genomic imbalances and patterns of karyotypic variability in mantle-cell lymphoma cell lines. Leuk Res 30:923\u2013934","journal-title":"Leuk Res"},{"key":"1377_CR31","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S1535-6108(03)00028-X","volume":"3","author":"A Rosenwald","year":"2003","unstructured":"Rosenwald A, Wright G, Wiestner A et al (2003) The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cells 3:185\u2013197","journal-title":"Cancer Cells"},{"key":"1377_CR32","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/hon.767","volume":"24","author":"F Bertoni","year":"2006","unstructured":"Bertoni F, Rinaldi A, Zucca E, Cavalli F (2006) Update on the molecular biology of mantle cell lymphoma. Hematol Oncol 24:22\u201327","journal-title":"Hematol Oncol"},{"key":"1377_CR33","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/j.biocel.2007.04.026","volume":"39","author":"F Bertoni","year":"2007","unstructured":"Bertoni F, Ponzoni M (2007) The cellular origin of mantle cell lymphoma. Int J Biochem Cell Biol 39:1747\u20131753","journal-title":"Int J Biochem Cell Biol"},{"key":"1377_CR34","unstructured":"Schmid M, Carson D (2000) Cell cycle regulation and hematological disorders. In: Beutler E, Lichtman MA (eds) 6th edn, McGraw-Hill Professional, pp 131\u2013140"},{"key":"1377_CR35","doi-asserted-by":"crossref","first-page":"18120","DOI":"10.1074\/jbc.M500758200","volume":"280","author":"MJ Mu\u00f1oz-Alonso","year":"2005","unstructured":"Mu\u00f1oz-Alonso MJ, Acosta JC, Richard C, Delgado MD, Sedivy J, Le\u00f3n J (2005) p21Cip1 and p27Kip1 Induce Distinct Cell Cycle Effects and Differentiation Programs in Myeloid Leukemia Cells. J Biol Chem 280:18120\u201318129","journal-title":"J Biol Chem"},{"key":"1377_CR36","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.4161\/cc.7.16.6464","volume":"15","author":"BW Konicek","year":"2008","unstructured":"Konicek BW, Dumstorf CA, Graff JR (2008) Targeting the eIF4F translation initiation complex for cancer therapy. Cell Cycle 15:2466\u20132471","journal-title":"Cell Cycle"},{"key":"1377_CR37","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1146\/annurev.cellbio.14.1.399","volume":"14","author":"NK Gray","year":"1998","unstructured":"Gray NK, Wickens M (1998) Control of translation initiation in animals. Annu Rev Cell Dev Biol 14:399\u2013458","journal-title":"Annu Rev Cell Dev Biol"},{"key":"1377_CR38","doi-asserted-by":"crossref","first-page":"6814","DOI":"10.1158\/0008-5472.CAN-07-0752","volume":"67","author":"O Larsson","year":"2007","unstructured":"Larsson O, Li S, Issaenko OA, Avdulov S et al (2007) Eukaryotic translation initiation factor 4E induced progression of primary human mammary epithelial cells along the cancer pathway is associated with targeted translational deregulation of oncogenic drivers and inhibitors. Cancer Res 67:6814\u20136824","journal-title":"Cancer Res"},{"key":"1377_CR39","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.biochi.2008.10.015","volume":"91","author":"D Baiz","year":"2009","unstructured":"Baiz D, Pozzato G, Dapas B et al (2009) Bortezomib arrests the proliferation of hepatocellular carcinoma cells HepG2 and JHH6 by differentially affecting E2F1, p21 and p27 levels. Biochimie 91:373\u2013382","journal-title":"Biochimie"},{"key":"1377_CR40","doi-asserted-by":"crossref","first-page":"11352","DOI":"10.1074\/jbc.M109062200","volume":"277","author":"Y Li","year":"2002","unstructured":"Li Y, Dowbenko D, Lasky LA (2002) AKT\/PKB phosphorylation of p21Cip\/WAF1 enhances protein stability of p21Cip\/WAF1 and promotes cell survival. J Biol Chem 277:11352\u201311361","journal-title":"J Biol Chem"},{"key":"1377_CR41","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/sj.onc.1205052","volume":"21","author":"S Ackler","year":"2002","unstructured":"Ackler S, Ahmad S, Tobias C, Johnson MD, Glazer RI (2002) Delayed mammary gland involution in MMTV-AKT1 transgenic mice. Oncogene 21:198\u2013206","journal-title":"Oncogene"},{"key":"1377_CR42","doi-asserted-by":"crossref","first-page":"6192","DOI":"10.1128\/MCB.00681-09","volume":"29","author":"X Li","year":"2009","unstructured":"Li X, Liu J, Gao T (2009) beta-TrCP-mediated ubiquitination and degradation of PHLPP1 are negatively regulated by Akt. Mol Cell Biol 29:6192\u20136205","journal-title":"Mol Cell Biol"},{"key":"1377_CR43","first-page":"1136","volume":"9","author":"MH Ma","year":"2003","unstructured":"Ma MH, Yang HH, Parker K et al (2003) The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 9:1136\u20131144","journal-title":"Clin Cancer Res"},{"key":"1377_CR44","doi-asserted-by":"crossref","unstructured":"Dreyling, MH and Hiddemann W (2009) Current treatment standards and emerging strategies in mantle cell lymphoma. Hematology, ASH Education Program Book: 542\u2013551","DOI":"10.1182\/asheducation-2009.1.542"},{"key":"1377_CR45","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S1097-2765(04)00156-X","volume":"14","author":"XM Sun","year":"2004","unstructured":"Sun XM, Butterworth M, MacFarlane M, Dubiel W, Ciechanover A, Cohen GM (2004) Caspase activation inhibits proteasome function during apoptosis. Mol Cell 14:81\u201393","journal-title":"Mol Cell"},{"key":"1377_CR46","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1182\/blood-2005-05-2091","volume":"107","author":"P P\u00e9rez-Gal\u00e1n","year":"2006","unstructured":"P\u00e9rez-Gal\u00e1n P, Rou\u00e9 G, Villamor N, Montserrat E, Campo E, Colomer D (2006) The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood 107:257\u2013264","journal-title":"Blood"},{"key":"1377_CR47","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/sj.leu.2404511","volume":"21","author":"O Weigert","year":"2007","unstructured":"Weigert O, Pastore A, Rieken M, Lang N, Hiddemann W, Dreyling M (2007) Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma. Leukemia 21:524\u2013528","journal-title":"Leukemia"},{"key":"1377_CR48","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1080\/10428190902856790","volume":"50","author":"O Weigert","year":"2009","unstructured":"Weigert O, Weidmann E, Mueck R et al (2009) A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma\u2014long-term results of a multicenter observation study. Leuk Lymphoma 50:716\u2013722","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"1377_CR49","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.bcp.2007.10.026","volume":"75","author":"LM Congdon","year":"2008","unstructured":"Congdon LM, Pourpak A, Escalante AM, Dorr RT, Landowski TH (2008) Proteasomal inhibition stabilizes topoisomerase IIalpha protein and reverses resistance to the topoisomerase II poison ethonafide (AMP-53, 6-ethoxyazonafide). Biochem Pharmacol 75(4):883\u2013890","journal-title":"Biochem Pharmacol"},{"issue":"12","key":"1377_CR50","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/nrc1505","volume":"4","author":"Y Ma","year":"2004","unstructured":"Ma Y, Hendershot LM (2004) The role of the unfolded protein response in tumour development: friend or foe? Nat Rev Cancer 4(12):966\u2013977","journal-title":"Nat Rev Cancer"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-011-1377-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-011-1377-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-011-1377-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,22]],"date-time":"2019-06-22T04:04:41Z","timestamp":1561176281000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-011-1377-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1,11]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["1377"],"URL":"https:\/\/doi.org\/10.1007\/s00277-011-1377-y","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1,11]]}}}